

2024 CFP SERVICES CHART

British Columbia

Alberta

Saskatchewan

Care plans / chronic disease management

\$100 per Comprehensive Annual Care Plan (CACP) (482,089 claims); \$60 per Standard Medication Management Assessment (SMMA) (71,654); \$20 per follow-up, max. 12 annually (2,530,120 for CACPs; 301,501 for SMMA); \$60 per SMMA for Diabetes and \$20 per follow-up, max. 4 annually (39,996 combined)

Medication reviews / management

\$60 per Medication Review - Standard (claims pending); \$70 per Medication Review - Pharmacist Consultation (claims pending); max. 2 annually for both combined; \$15 per follow-up, max. 4 annually (claims pending)

Medication reviews a component of CACPs and SMMA (see Care plans above)

\$60 per Medication Assessment (seniors) (10,555 claims), max. 1 annually; \$20 per follow-up, max. 2 annually (3,295); \$60 per Medication Assessment (home care) (1,190); \$6.25/week for compliance packaging following an assessment (93,059 for seniors, 39,007 for home care)

Pharmaceutical opinions

Vaccination

\$12.10 (1,262,708 claims for flu, Jul. 2023-Jun. 2024, claims pending for pneumococcal, other); \$18 for COVID-19 (1,543,360, Jul. 2023-Jun. 2024); \$11.41 for non-publicly funded vaccines as of Oct. 14, 2022 (claims n/a)

- \$13 (884,889 claims for flu, 10,284 for pneumococcal, 15,911 for Tdap); \$17 for COVID-19, reduced to \$13 as of Apr. 1, 2024 (774,365)
- In senior congregate care settings as of April 2024, \$17 for flu, COVID, pneumococcal and RSV
- Authority for other vaccinations, inc. travel vaccines; for RSV as of Oct. 2024

\$14 for flu (164,091 claims); \$20 for COVID-19 (88,919); authority for other vaccinations, inc. travel vaccines

Administration of drugs by injection

\$11.41 (exc. allergy serums and substances for cosmetic use; claims pending)

\$20 (434,104 claims)

\$13 for medroxyprogesterone and Evusheld (5,924 claims); increased to \$14 as of June 2024, also for antipsychotics, Sublocade and testosterone

Prescribing: renewals and adaptations

\$10 to renew (claims pending) or adapt (claims pending), combined max. 2/drug every 6 months or renewal for up to 30 days or same duration as prescribed for controlled substances

\$20 to renew or adapt (inc. altering insulin orders and discontinuations) (1,539,321 claims for renewals; 210,655 for adaptations)

\$6 to renew, alter dosage form, max. 4/28 days, alter missing information, or enhance safety and effectiveness max. 1/28 days; \$6 to continue prescription in emergency (interruption in drug therapy), max. 4/28 days; \$25 for medication reconciliations with prescribing (408,365 claims for all authorities)

Prescribing: minor ailments and common conditions

\$20 per assessment with or without prescribing for 21 conditions and contraception inc. emergency contraception, as part of Pharmacare daily billing max. of \$78 (claims pending)

As part of CACPs and SMMA by those with additional prescribing authority (APA); outside of CACPs and SMMA, \$25 per assessment resulting in a prescription by those with APA (claims inc. under prescribing for initial access)

\$18 per assessment resulting in a prescription for 26 conditions (42,742 claims); increased to \$25 as of June 2024 for 30 conditions

Prescribing: initial access or to manage ongoing therapy

- Pharmacists with APA have authority to prescribe any Schedule 1 drug or vaccine
- \$25 per assessment for initiating prescription by those with APA (781,407 claims); \$20 per emergency prescription (42,979); \$20 per continuity of care prescription during declared "state of emergency" (3,118)

- Authority to assess and prescribe in emergencies; authority to assess and prescribe for preventable diseases
- In pilot pharmacies, \$25 per assessment with or without prescribing for strep throat (plus POCT, see below) and ear infection

COVID-19 prevention and treatment

\$30 for Paxlovid assessment (claims pending), discontinued Dec. 31, 2023; \$25 for follow-ups, discontinued Mar. 31, 2023

- \$10 plus dispensing fee to dispense Paxlovid (11,673 claims), discontinued May 2024
- Pharmacists with APA can prescribe Paxlovid

- \$18 increased to \$25 as of Jun. 2024 per assessment with or without prescribing for Paxlovid (343 claims)
- \$20 distribution fee for Evusheld

Therapeutic substitution

\$17.20 (claims pending)

\$20 (claims included under adaptations)

\$18 per substitution in extraordinary circumstances

Trial prescriptions & refusals to fill

\$10 per trial (claims pending); \$20 per refusal (claims pending)

\$12.15 per trial (302 claims) plus \$20 for follow-up (1,672); \$20 per refusal (3,119)

\$12.15 per trial plus \$750 for follow-up (6 claims); 1.5X dispensing fee max. \$18.23 per refusal (29)

Deprescribing

\$20 (claims inc. under adaptations); as of Feb. 2025, authority restricted to pharmacists with APA

Laboratory tests

Authority to order and interpret lab tests for medication management as of Aug. 30, 2024

Authority to order and interpret lab tests

Authority to order lab tests

Point-of-care testing (POCT)

\$75 per case for distribution of COVID-19 rapid antigen tests

- Authority for POCT within scope of practice
- \$60 per case for distribution of COVID-19 rapid antigen tests

In pilot pharmacies, \$10 per POCT for strep throat plus \$25 for test cartridge

Smoking cessation

\$30 (3 dispensing fees) per 12-week course of treatment

\$60 for SMMA for Tobacco Cessation; \$20 per follow-up, max. 4 follow-ups annually (48,874 claims combined)

- Up to \$300 annually (\$1 [individual] or \$2 [group] per minute) for Partnership to Assist with the Cessation of Tobacco (PACT) (3,317 claims)
- Authority to prescribe for smoking cessation as part of minor ailments

Opioid harm reduction

- \$7.70 plus dispensing fee per witnessed dose of methadone (claims pending)
- Govt-funded naloxone available through pharmacies

\$12.15 for dispensing of govt-funded naloxone (143,159 claims)

- \$3.50/day increased to \$7.50 as of June 2024 per witnessed dose for Methadone Managed Care (44,155 claims) and Suboxone Managed Care (12,970), max. 7 weekly
- \$16 for education for govt-funded naloxone at selected pharmacies (2,826)

Other services

\$15 per Biosimilar Patient Support service (claims pending)

\$20 per Assessment to Screen and/or Test for Infectious Disease, max. 5/day/pharmacy (not a POCT and for COVID-19 only; 673,619 claims), discontinued Oct. 1, 2023

- 1.5X dispensing fee max. \$18.23 for seamless care (402 claims)
- \$3.50/day for Direct Observed Therapy for Hepatitis C drugs (73)
- \$18 per Biosimilar Insulin Transition (3,119)

Manitoba	Ontario	Quebec	New Brunswick
----------	---------	--------	---------------

NOTES: All content in **RED** indicates public funding limited to eligible beneficiaries of the provincial drug plan. Information current as of October 18, 2024. Claims data are for fiscal year ending March 31, 2024. In **B.C., Manitoba, Ontario and P.E.I.**, claims data pending at time of publication. In **Manitoba**, claims for vaccinations may include non-publicly funded vaccines for HPV and pneumococcal. In **Quebec**, private insurance plans pay the same professional service fees as the public plan, for most but not all of the services listed here. In all provinces, pharmacists have authority to prescribe emergency refills.

In pilot pharmacies, authority for assessments and follow-ups for management of asthma, COPD, cardiovascular disease, diabetes

\$60 for MedsCheck Annual (claims pending); \$75 for MedsCheck for Diabetes, max. 1 annually (claims pending); \$150 for MedsCheck at Home, max. 1 annually (claims pending); \$25 per follow-up (claims pending)

\$52.50 per PharmaCheck (seniors and low-income), max. 1 annually (12,879 claims)

\$15 per Pharmaceutical Opinion (claims pending)

\$24.60 (168,112 claims). As of Apr. 2024, program reduced to one type of Opinion, i.e., to initiate a therapy

\$13 for flu (179,939 claims); \$20 for COVID-19 (188,345); \$7 for other publicly funded vaccines (3,286 for pneumococcal; 1,098 for HPV; 3,308 for Tdap; 414 for Td)

\$8.50 for flu (1,990,778 claims, Oct.2023-Mar.2024); \$13 for COVID-19 (2,259,679, Jan.-Dec. 2023); authority for other vaccinations inc. RSV and travel vaccines

\$16.44 when administered by a pharmacist or \$13.56 by authorised staff, increased to \$17.26 and \$14.24 as of Apr. 2024 (678,000 claims for flu, 498,000 for COVID-19, 114,000 for shingles, 122,000 for other)

\$13 (139,591 claims for flu, 154,332 for COVID-19, 5,108 for pneumococcal); authority for other vaccinations, inc. travel vaccines

Authority to administer drugs by injection

Authority to administer certain substances within specified limitations

\$21.33 increased to \$22.40 as of Apr. 2024 for demonstration purposes (8,994 claims) or in emergencies (637)

Authority to administer drugs by injection

Authority for continuity of care prescribing and prescription adaptations

Authority to renew and adapt

\$14.79 increased to \$15.53 as of Apr. 2024 per renewal (1,451,501 claims); \$23.43 increased to \$24.60 as of Apr. 2024 per adaptation (740,937)

\$20 to renew batch of 4 or more prescriptions, \$15 for 3 Rx, \$10 for 1 or 2 Rx, max. 4 annually (171,502 claims); authority to adapt

\$20 per assessment for UTIs with or without prescribing (claims pending); 13 conditions in total

\$19 (in-person) or \$15 (virtual) per assessment with or without prescribing for 19 conditions (656,764 claims, Jan.-Dec. 2023)

\$23.43 increased to \$24.60 as of Apr. 2024 per assessment with or without prescribing for herpes zoster, influenza and COVID-19; \$18.94 increased to \$19.89 as of Apr. 2024 for other common conditions; 35 conditions in total (1,110,433 claims)

- \$20 per assessment with or without prescribing for 9 conditions, max. 1-3 annually (10,482 claims for UTIs, 2,431 for conjunctivitis, 2,231 for cold sores, 4,681 for remaining); \$20 per assessment or change in therapy for mild acne, max. 3 annually (363) and \$12 for follow-up (claims n/a); 33 conditions in total
- \$20 per assessment or change in therapy for Contraception Management, max. 3 annually (1,597); \$12 for follow-up (claims n/a)

Authority for prescribing by Extended Practice pharmacists within the scope of their specialty; authority to prescribe in "state of emergency"

- \$19 per assessment with or without prescribing oseltamivir (claims pending)
- Authority to initiate Schedule 1 smoking cessation therapy; see Smoking cessation below for funding details

- \$18.34-\$21.89 increased to \$19.26-\$24.24 as of Apr. 2024 per initial consult to reach therapeutic target; \$23.67 increased to \$24.85 per follow-up (\$11.84 increased to \$12.43 for additional therapeutic indication), max. 2 annually (308,383 claims combined)
- \$21.89 increased to \$22.98 per initial consult for INR; \$18.94 increased to \$19.89 per monthly follow-up (189,816 combined)
- \$19.34 increased to \$19.89 to prescribe for emergency contraception (126,847)
- \$21.33 increased to \$22.40 to prescribe and administer salbutamol and nonprescription drugs in emergency (637)

- Authority to assess and prescribe in emergencies; for preventable diseases (inc. RSV as of Oct. 2024)
- In pilot pharmacies, authority to perform assessment with or without prescribing for strep throat (plus POCT, see below)

\$14 or usual dispensing fee if lower to dispense Paxlovid (claims pending)

- \$19 per assessment with or without prescribing Paxlovid (claims pending)
- Up to \$31 to prepare and dispense remdesivir (claims pending)

\$23.43 increased to \$24.60 as of Apr. 2024 per assessment with or without prescribing Paxlovid as part of minor ailments

\$20 per assessment with or without prescribing Paxlovid, or to adapt, complete or correct prescription, max. 3 annually (4,885 claims)

\$18.94 increased to \$19.89 as of Apr. 2024 (116,510 claims)

Authority to substitute

\$15 per refusal as part of Pharmaceutical Opinions (see above)

Separate billings discontinued Feb. 2023 for trial prescriptions and Mar. 2023 for refusals

\$18.34 increased to \$19.26 as of Apr. 2024 (38,190 claims)

Authority to order tests, receive and follow up with results

Authority to order and interpret lab tests

Authority to order and administer lab tests pending changes to Regional Health Authority Act

- Authority to perform certain POCTs (glucose, HbA1C, lipids, PT/INR) for medication management
- \$42 per in-store COVID-19 PCR test; \$20 per screening if patient ineligible for PCRT (claims pending)

Authority to obtain throat specimen for medication management

- Authority to perform, interpret and communicate results of POCT for medication management
- Authority to witness self-administration of COVID-19 rapid antigen test and certify result
- In pilot pharmacies, authority for strep-throat POCT

\$100 to assess and prescribe (1,486 claims); \$20 per follow-up, max. 9 annually (2,615). Funded under a social impact bond

\$40 for initial consult; \$15 per primary follow-up, max. 3; \$10 per secondary follow-up, max. 4; total max. \$125 annually (claims pending)

\$18.94 increased to \$19.89 as of Apr. 2024 to prescribe for smoking cessation (claims inc. under minor ailments)

Authority to prescribe for nicotine dependence as part of minor ailments

Govt-funded naloxone available through participating pharmacies

- \$10 for dispensing govt-funded naloxone; \$25 for training for injectable naloxone
- For methadone, dispensing fee per daily dose; for buprenorphine/naloxone, dispensing fee for each of: daily witnessed dose; all carry doses dispensed at one time; any combination of witnessed and carry doses dispensed at one time

\$21.33 increased to \$22.40 as of Apr. 2024 to demonstrate use of govt-funded naloxone (25,817)

- \$42 for specimen collection for lab COVID-19 PCR test; \$15 for handling self-collected specimen for PCRT, increased to \$35 when pharmacist is ordering clinician or \$20 for digital self-collection; \$20 per screening if PCRT-ineligible (claims pending)
- Authority to perform procedure below dermis with lancet-type device to demonstrate proper use; and to administer certain substances by inhalation
- \$15 per Biosimilars Patient Support service (claims pending)

\$10.18 increased to \$10.38 as of Apr. 2024 per transmission of medication profile (91,316 claims); \$29.13 increased to \$30.59 per hospital discharge support (71,964); \$46.86 increased to \$49.20 per prescriber-requested consult (32,207); \$34.97 increased to \$36.72 per week per palliative care support (14,078); \$21.66 increased to \$22.74 per consult for medical abortion (657); \$36.68 increased to \$49.20 per on-call service (claims n/a)

Sources: Provincial pharmacy associations, provincial ministries of health

2024 CFP SERVICES CHART

Services, fees and claims data for government-sponsored pharmacy programs as of October 18, 2024; claims data for fiscal year April 1, 2023 to March 31, 2024 unless otherwise stated. Check for updates at cfpnet.ca

	Nova Scotia	Prince Edward Island	Newfoundland and Labrador
Care plans / chronic disease management	For pharmacies with a Community Pharmacy Primary Care Clinic (CPPCC), \$125 per assessment and \$20 per follow-up for management of ADHD, asthma, COPD, cardiovascular disease, diabetes, non-cancer pain, obesity		
Medication reviews / management	<ul style="list-style-type: none"> \$52.50 per Basic Medication Review (5,201 claims); \$150 per Advanced Medication Review for seniors (4,057); \$20 per follow-up, max. 2 annually (992) In CPPCCs, \$150 per Complex Medication Review and \$20 per follow-up 	\$52.50 per Basic Medication Review (claims pending); \$65 per Diabetes Medication Review (claims pending); \$20 per follow-up for Basic Medication Review, max. 4 annually (claims pending); \$25 per follow-up for Diabetes Medication Review, max. 4 annually (claims pending)	\$52.50 per Medication Review, max. 72/ pharmacy annually (2,375 claims)
Pharmaceutical opinions			
Vaccination	<ul style="list-style-type: none"> \$12.85 increased to \$13 as of Apr. 2024 (211,437 claims); \$18 for COVID-19 (262,685); \$18 for meningococcal B and pneumococcal as of May 2023 (claims pending) In CPPCCs, \$18 for all publicly funded vaccines exc. Grade 7 vaccinations; additional \$22 for complex vaccinations that meet criteria 	\$13 for flu (claims pending); \$20 for COVID-19 (claims pending); \$20 for Shingrix (claims pending); authority for other vaccinations, inc. travel vaccines	\$13 for flu (80,110 claims); \$17 for COVID-19 (65,513); authority for other vaccinations, inc. travel vaccines
Administration of drugs by injection	<ul style="list-style-type: none"> Authority to administer drugs by injection In CPPCCs, \$20 for basic and \$42 for complex injections 	Authority to administer drugs by injection	Authority to administer drugs by injection
Prescribing: renewals and adaptations	\$20 to renew batch of 4 or more prescriptions (16,116 claims), \$12 for up to 3 Rx (211,509); \$14 per Prescription Adaptation (9,963). Prior to Jul. 2023, funding limited to provincial drug-plan beneficiaries	\$20 per renewal, max. 6 annually (claims pending); 1.3X dispensing fee up to \$16.50 per adaptation (claims pending)	<ul style="list-style-type: none"> As of Apr. 2023, \$20 to renew batch of 4 or more prescriptions (21,652 claims), \$15 for 3 Rx (11,493), \$10 for 1 or 2 Rx (132,961), max. 4 annually \$11.96 or \$12 per Medication Management adaptation (6,840 claims)
Prescribing: minor ailments and common conditions	<ul style="list-style-type: none"> \$20 per assessment with or without prescribing for shingles (1,947 claims), Lyme disease (5,762), UTIs (19,964), max. 2 annually; 35 conditions in total; in CPPCCs, \$20 per assessment with or without prescribing for 27 conditions \$20 per annual assessment with or without prescribing for Contraception Management (2,566); \$20 per follow-up with change, max. 1 annually; \$12 per follow-up with no change, max. 1 annually (1,484); in CPPCCs, \$20 per assessment for emergency contraception 	\$25 per assessment with or without prescribing for 35 conditions, inc. hormonal contraception and emergency contraception (claims pending)	<ul style="list-style-type: none"> As of Apr. 2023, \$20 per assessment with or without prescribing for 9 conditions, max. 2-4 annually (4,516 claims for cold sores, 3,370 for conjunctivities, 2,809 for GERD, 4,301 for remaining); 33 conditions in total As of Apr. 2023, \$20 per assessment with or without prescribing for hormonal contraception, max. 3 annually (721 claims); \$20 per follow-up (268)
Prescribing: initial access or to manage ongoing therapy	<ul style="list-style-type: none"> Authority to assess and prescribe in emergencies; for diagnosis provided by primary care provider; for preventable diseases (inc. RSV) As of May 2024, authority to assess and prescribe for strep throat (inc. POCT, see below); in CPPCCs, \$20 without POCT, \$35 with POCT plus cost of test cartridge + 10% As of Jul. 2024, authority to assess and prescribe for HIV PrEP 	Authority to assess and prescribe in emergencies	Authority to assess and prescribe for preventable diseases
COVID-19 prevention and treatment	<ul style="list-style-type: none"> \$20 per assessment with or without prescribing budesonide (1,402 claims) \$3.50 plus dispensing fee to dispense Paxlovid (claims n/a), discontinued May 2024 	<ul style="list-style-type: none"> \$25 per assessment with or without prescribing Paxlovid as part of common ailments (claims pending) \$5 plus dispensing fee to dispense Paxlovid (claims pending) 	<ul style="list-style-type: none"> \$20 to assess eligibility for Paxlovid (4,264 claims) \$7.50 to provide rapid antigen test (252)
Therapeutic substitution	\$26.25 (20,015 claims). Prior to Jul. 2023, funding limited to provincial drug-plan beneficiaries	1.3X dispensing fee max. \$16.50 (claims pending)	\$11.96 or \$12 (usual dispensing fee) (claims n/a)
Trial prescriptions & refusals to fill	\$14 per refusal (78 claims)	1.3X dispensing fee max. \$16.50 per refusal (claims pending)	\$23.92 or \$24 per refusal (1 claim)
Deprescribing	Authority to taper doses as part of adaptations; in CPPCCs, \$52.50 per assessment for PPIs and \$150 for BzRAs, and \$20 per follow-up		\$23 per assessment for SaferMedsNL (1,179 claims for PPIs, 518 for sedatives); \$10 per follow-up (207 for PPIs, 72 for sedatives)
Laboratory tests	In CPPCCs, authority to order lab tests	Authority to order lab tests pending health system operationalization	
Point-of-care testing (POCT)	<ul style="list-style-type: none"> Authority to perform POCT for medication management \$50 per month for Community Pharmacist-led Anticoagulation Management Service inc. INR test and dose adjustments (19,668 claims) Authority to administer COVID-19 rapid antigen test and certify result for travel As of May 2024, strep-throat POCT as part of assessment (see "Prescribing: initial access") In CPPCCs, \$15 per panel test for A1C and lipids (tests supplied at no charge) 	Authority to perform glucose, HbA1C and INR tests pending regulations	
Smoking cessation	Authority to prescribe for smoking cessation as part of minor ailments; in CPPCCs, \$40 per initial consult for support program and \$15 per follow-up; \$20 for medication assessment only	Authority to prescribe for smoking cessation as part of common ailments	As of Apr. 2023, \$20 per assessment with or without prescribing for quit-smoking therapies as part of common conditions (1,252 claims)
Opioid harm reduction	\$25 for dispensing and education for govt-funded naloxone (174 claims)		\$3 per carry for opioid agonist therapy (OAT, claims n/a); \$50 per delivery of OAT for those isolating due to COVID-19 (6 claims)
Other services			<ul style="list-style-type: none"> \$50 per assessment and dispensing for medical abortion (359 claims) Authority to administer drugs by inhalation

Sources: Provincial pharmacy associations, provincial ministries of health

Made possible with financial support from



Prepared by the Canadian Foundation for Pharmacy
www.cfpnet.ca